A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

NCT07281937 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing the effects of a weekly oral medication called ecnoglutide (VRB-101) in adults who have obesity or overweight with weight-related health issues.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 206 people

Who can join Ages 18–80 · all sexes

Timeline Started 2025-11 · est. completion 2026-08

Where 22 sites · United States

What this study is testing ClinicalTrials.gov NCT07281937 ↗

Description as written by the study sponsor.

The aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.

Treatments tested

VRB-101 also known as Oral Ecnoglutide Drug

VRB-101 tablets will be administered orally.
Placebo Drug

Placebo tablets will be administered orally.

Main thing measured	Mean percent change from baseline in body weight
Sponsor	Verdiva Bio Dev Limited
Conditions studied	Obesity, Overweight
GLP-1 drugs	ecnoglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07281937 ↗